Health economic consequences related to the diagnosis of fibromyalgia syndrome

Arthritis and Rheumatism

Volumn 58, Issue 3, 2008, Pages 895-902

  Annemans, L ^a,b,c   Wessely, S ^d   Spaepen, E ^a   Caekelbergh, K ^a   Caubere J P ^e   Le Lay, K ^e   Taieb C ^e,f  

^a IQVIA   (United States)

^b GHENT UNIVERSITY   (Belgium)

^c FREE UNIVERSITY OF BRUSSELS   (Belgium)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e Centre d'Immunologie Pierre Fabre   (France)

^f Santé Publique and Qualité de Vie ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; NONSTEROID ANTIINFLAMMATORY AGENT; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ARTICLE; CONSULTATION; CONTROLLED STUDY; COST CONTROL; DRUG COST; FIBROMYALGIA; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; IMAGING; PATIENT REFERRAL; PRIORITY JOURNAL; UNITED KINGDOM;

DIAGNOSTIC SERVICES; DRUG THERAPY; EARLY DIAGNOSIS; FIBROMYALGIA; GREAT BRITAIN; HEALTH CARE COSTS; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; NATIONAL HEALTH PROGRAMS; OFFICE VISITS; REFERRAL AND CONSULTATION;

EID: 40549121925     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.23265     Document Type: Article

References (23)

1. White KP, Harth M. Classification, epidemiology, and natural history of fibromyalgia [review]. Curr Pain Headache Rep 2001;5:320-9.
2. Hadler NM. "Fibromyalgia" and the medicalization of misery [review]. J Rheumatol 2003;30:1668-70.
3. Hadler NM. Fibromyalgia, chronic fatigue, and other iatrogenic diagnostic algorithms: do some labels escalate illness in vulnerable patients? [review]. Postgrad Med 1997;102:161-2, 165-6, 171-2.
4. Hadler NM. The dangers of the diagnostic process: iatrogenic labelling as in the fibrositis paralogism. In: Hadler N, editor. Occupational musculoskeletal disorders. New York: Raven Press; 1993. p. 160-71.
5. Ehrlich GE. Pain is real: fibromyalgia isn't. J Rheumatol 2003;30:1666-7.
6. Penrod JR, Bernatsky S, Adam V, Baron M, Dayan N, Dobkin PL. Health services costs and their determinants in women with fibromyalgia. J Rheumatol 2004;31:1391-8.
7. Goldenberg DL. Fibromyalgia syndrome a decade later: what have we learned? [review]. Arch Intern Med 1999;159:777-85.
8. White KP, Speechley M, Harth M, Ostbye T. The London Fibromyalgia Epidemiology Study: direct health care costs of fibromyalgia syndrome in London, Canada. J Rheumatol 1999;26:885-9.
9. De Girolamo G. Epidemiology and social costs of low back pain and fibromyalgia. Clin J Pain 1991;7:S1-7.
10. Robinson RL, Birnbaum HG, Morley MA, Sisitsky T, Greenberg PE, Wolfe F. Depression and fibromyalgia: treatment and cost when diagnosed separately or concurrently. J Rheumatol 2004;31:1621-9.
11. Boonen A, van den Heuvel R, van Tubergen A, Goossens M, Severens JL, van der Heijde D, et al. Large differences in cost of illness and wellbeing between patients with fibromyalgia, chronic low back pain, or ankylosing spondylitis. Ann Rheum Dis 2005;4:396-402.
12. Robinson RL, Birnbaum HG, Morley MA, Sisitsky T, Greenberg PE, Claxton AJ. Economic cost and epidemiological characteristics of patients with fibromyalgia claims. J Rheumatol 2003;30:1318-25.
13. Twine C, Barthelmes L, Gateley CA. Kylie Minogue's breast cancer: effects on referrals to a rapid access breast clinic in the UK. Breast 2006;15:667-9.
14. Miller LS, Martin BC. Current and future forecasts of service use and expenditures of Medicaid-eligible schizophrenia patients in the state of Georgia. Schizophr Bull 2004;30:983-95.
15. Someya T, Suzuki Y, Sham PC, Tang SW. Forecasting the number of inpatients with schizophrenia. Psychiatry Clin Neurosci 2004;58:573-8.
16. Ocana-Riola R. [Efficacy of time series analysis in health planning for cancer in Spain] Aten Primaria 2004;34:15-9. In Spanish.
17. Pereira A. Performance of time-series methods in forecasting the demand for red blood cell transfusion. Transfusion 2004;44:739-46.
18. Hughes G, Martinez C, Myon E, Taieb C, Wessely S. The impact of a diagnosis of fibromyalgia on health care resource use by primary care patients in the UK: an observational study based on clinical practice. Arthritis Rheum 2006;54:177-83.
19. Wood L, Martinez C. The general practice research database: role in pharmacovigilance [review]. Drug Saf 2004;27:871-81.
20. National Health Service (NHS). National Reference Department of Health. NHS reference costs 2003 and national tariff 2004. February 5, 2004. URL: http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/ PublicationsPolicyandGuidance/DH_4070195.
21. Royal London NHS (National Health Service) Trust. Department of Health Published. Price Tariffs 1999. January 1, 2000. p. 157. URL: http://www.dh.gov.uk/en/PublicationsandStatistics/Publications/ PublicationsPolicyAndGuidance/DH_4007921.
22. British National Formulary (BNF) 2004. London British Medical Association and the Royal Pharmaceutical Society of Great Britain. URL: http://www.bnf.org/bnf.
23. Allison PD. Fixed effects regression methods for longitudinal data using SAS. Cary, NC: SAS Institute; 2005.